Display options
Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Affiliations

  1. Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
  2. Gustave Roussy Cancer Campus ; Villejuif, France.
  3. INSERM; U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
  4. INSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Laboratory of Integrative Cancer Immunology; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
  5. Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM ; U1015 , Villejuif, France.
  6. Department of Medicine; Division of Oncology; Stanford University ; Stanford, CA, USA.
  7. INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou ; AP-HP ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
  8. Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.

PMID: 25949870 PMCID: PMC4368132 DOI: 10.4161/2162402X.2014.985940

Abstract

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activate lethal receptors at the plasma membrane of cancer cells, they can opsonize neoplastic cells to initiate a tumor-targeting immune response, or they can be harnessed to specifically deliver toxins or radionuclides to transformed cells. As an indication of the success of this immunotherapeutic paradigm, international regulatory agencies approve new tumor-targeting mAbs for use in cancer patients every year. Moreover, the list of indications for previously licensed molecules is frequently expanded to other neoplastic disorders as the results of large, randomized clinical trials become available. Here, we discuss recent advances in the preclinical and clinical development of tumor-targeting mAbs for oncological indications.

Keywords: 5-fluorouracil; ADCC; Food and Drug Administration; FOLFIRI; acute lymphocytic leukemia; AML; acute myeloid leukemia; BiTE; anaplastic large-cell lymphoma; ALL; antibody-dependent cell-mediated cytotoxicity; ALCL; bevacizumab; bispecific T-cell engager; CDC; cetuximab; chronic lymphocytic leukemia; CRC; coagulation factor III; FDA; colorectal carcinoma; DLBCL; complement-dependent cytotoxicity; CLL; diffuse large B-cell lymphoma; EGFR; epidermal growth factor receptor; F3; folinic acid; hepatocellular carcinoma; HHV-8; human herpesvirus-8; IL; interleukin; mAb; irinotecan; FOLFOX; mantle cell lymphoma; MDS; monoclonal antibody; MMAE; monomethyl auristatin E; MCL; myelodysplastic syndrome; NHL; non-Hodgkin's lymphoma; NSCLC; non-small cell lung carcinoma; ORR; obinutuzumab; overall response rate; OS; overall survival; PFS; oxaliplatin; HCC; phosphoinositide-3-kinase; RCC; progression-free survival; PI3K; ramucirumab; renal cell carcinoma; SLL; rituximab; small lymphocytic leukemia; TAA; trastuzumab; tumor-associated antigen

References

  1. Blood. 2009 Sep 24;114(13):2721-9 - PubMed
  2. Br J Cancer. 2010 Oct 12;103(8):1154-62 - PubMed
  3. Cancer Res. 2007 Jul 1;67(13):6253-62 - PubMed
  4. Lancet Oncol. 2010 Feb;11(2):155-64 - PubMed
  5. Cancer Pract. 1998 May-Jun;6(3):195-7 - PubMed
  6. Cancer Res. 2004 Aug 15;64(16):5760-6 - PubMed
  7. Lancet Oncol. 2010 Feb;11(2):108-9 - PubMed
  8. J Clin Oncol. 2014 May 10;32(14):1445-52 - PubMed
  9. Oncoimmunology. 2012 Sep 1;1(6):810-821 - PubMed
  10. Oncologist. 2014 Apr;19(4):350-1 - PubMed
  11. J Clin Oncol. 2010 Jul 10;28(20):3239-47 - PubMed
  12. Oncoimmunology. 2014 Jan 1;3(1):e28185 - PubMed
  13. Am J Clin Oncol. 2015 Aug;38(4):422-30 - PubMed
  14. Clin Cancer Res. 2010 Jan 15;16(2):699-710 - PubMed
  15. Cancer Biol Ther. 2010 Apr 15;9(8):618-31 - PubMed
  16. Clin Cancer Res. 2010 Sep 1;16(17 ):4331-8 - PubMed
  17. Lancet. 2013 Jan 26;381(9863):303-12 - PubMed
  18. Sci Signal. 2014 Mar 25;7(318):ra29 - PubMed
  19. Cancer Res. 2014 Feb 15;74(4):1214-26 - PubMed
  20. Nat Rev Drug Discov. 2005 May;Suppl:S10-1 - PubMed
  21. N Engl J Med. 2013 Aug 8;369(6):507-16 - PubMed
  22. Cell Res. 2010 Jan;20(1):34-50 - PubMed
  23. Cancer Control. 2014 Jan;21(1):80-9 - PubMed
  24. Cancer Res. 2013 Oct 1;73(19):6013-23 - PubMed
  25. Oncoimmunology. 2013 Oct 1;2(10):e26527 - PubMed
  26. Lancet Oncol. 2013 Nov;14(12):1208-15 - PubMed
  27. Lancet Oncol. 2014 Jun;15(7):747-56 - PubMed
  28. Nat Rev Drug Discov. 2013 Nov;12 (11):829-46 - PubMed
  29. Oncoimmunology. 2013 Jul 1;2(7):e24850 - PubMed
  30. Cancer Biol Ther. 2008 Mar;7(3):333-9 - PubMed
  31. Blood. 2008 Feb 15;111(4):2170-80 - PubMed
  32. Arch Dis Child. 2000 Aug;83(2):143-5 - PubMed
  33. Oncoimmunology. 2013 Mar 1;2(3):e23510 - PubMed
  34. Br J Haematol. 2011 Mar;152(5):579-92 - PubMed
  35. Pharmacol Ther. 2012 Dec;136(3):334-42 - PubMed
  36. J Cancer. 2011;2:309-16 - PubMed
  37. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 - PubMed
  38. J Clin Oncol. 2011 Jun 20;29(18):2493-8 - PubMed
  39. Mol Cancer Ther. 2014 Oct;13(10 ):2253-63 - PubMed
  40. Lancet. 2014 Aug 23;384(9944):665-73 - PubMed
  41. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
  42. Blood. 2007 Jul 15;110(2):616-23 - PubMed
  43. Clin Cancer Res. 2001 Jun;7(6):1490-6 - PubMed
  44. Oncoimmunology. 2014 Feb 01;3:e28386 - PubMed
  45. Nat Rev Immunol. 2009 Oct;9(10):729-40 - PubMed
  46. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5998-6003 - PubMed
  47. Oncoimmunology. 2013 Nov 1;2(11):e26383 - PubMed
  48. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  49. Cancer Res. 2011 Jan 15;71(2):496-505 - PubMed
  50. N Engl J Med. 2014 Feb 20;370(8):734-43 - PubMed
  51. Cancer Res. 2013 Nov 1;73(21):6494-503 - PubMed
  52. J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 - PubMed
  53. J Clin Oncol. 2002 May 15;20(10 ):2453-63 - PubMed
  54. N Engl J Med. 2014 Mar 20;370(12):1160-2 - PubMed
  55. Lancet Oncol. 2013 Dec;14(13):1326-36 - PubMed
  56. Invest Ophthalmol Vis Sci. 2013 May 01;54(5):3657-65 - PubMed
  57. N Engl J Med. 2013 Jul 4;369(1):32-42 - PubMed
  58. Blood. 2000 Aug 15;96(4):1259-66 - PubMed
  59. Oncoimmunology. 2014 Jan 1;3(1):e27048 - PubMed
  60. Clin Cancer Res. 2012 Aug 15;18(16):4415-24 - PubMed
  61. Lancet Oncol. 2014 Oct;15(11):1269-78 - PubMed
  62. Oncoimmunology. 2014 Jan 1;3(1):e27482 - PubMed
  63. Br J Haematol. 2000 Oct;111(1):277-9 - PubMed
  64. Lancet Oncol. 2014 Oct;15(11):1224-35 - PubMed
  65. Oncoimmunology. 2012 Sep 1;1(6):957-958 - PubMed
  66. J Clin Invest. 2013 Dec;123(12):5098-103 - PubMed
  67. Lancet Oncol. 2012 Oct;13(10):1055-62 - PubMed
  68. J Clin Oncol. 2014 May 1;32(13):1302-8 - PubMed
  69. Oncoimmunology. 2013 Mar 1;2(3):e23402 - PubMed
  70. Future Oncol. 2012 Jun;8(6):687-95 - PubMed
  71. Clin Cancer Res. 2013 Apr 1;19(7):1858-72 - PubMed
  72. Oncoimmunology. 2014 Jan 1;3(1):e27297 - PubMed
  73. Oncoimmunology. 2013 Feb 1;2(2):e23138 - PubMed
  74. Oncoimmunology. 2013 Jan 1;2(1):e22620 - PubMed
  75. Nat Rev Mol Cell Biol. 2011 Jun;12 (6):385-92 - PubMed
  76. Oncoimmunology. 2013 Jan 1;2(1):e22789 - PubMed
  77. Oncoimmunology. 2014 Mar 17;3:e28245 - PubMed
  78. Oncogene. 2013 Sep 12;32(37):4331-42 - PubMed
  79. Oncoimmunology. 2012 Nov 1;1(8):1445-1447 - PubMed
  80. BMJ. 2012 Dec 12;345:e8346 - PubMed
  81. Clin Cancer Res. 2008 Mar 1;14 (5):1296-302 - PubMed
  82. Expert Rev Hematol. 2014 Oct;7(5):545-57 - PubMed
  83. J Oncol Pharm Pract. 2015 Dec;21(6):451-67 - PubMed
  84. Clin Cancer Res. 2008 Jan 15;14 (2):502-8 - PubMed
  85. J Clin Oncol. 2010 Apr 1;28(10 ):1749-55 - PubMed
  86. Semin Hematol. 2014 Jul;51(3):219-27 - PubMed
  87. Lancet Oncol. 2012 May;13(5):528-38 - PubMed
  88. Expert Opin Investig Drugs. 2009 Jul;18(7):1025-33 - PubMed
  89. Front Biosci (Landmark Ed). 2011 Jan 01;16:277-306 - PubMed
  90. Oncogene. 2012 Apr 12;31(15):1869-83 - PubMed
  91. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  92. MAbs. 2009 May-Jun;1(3):222-9 - PubMed
  93. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42 - PubMed
  94. Br J Haematol. 2013 Oct;163(2):182-93 - PubMed
  95. Oncoimmunology. 2013 Oct 1;2(10):e27025 - PubMed
  96. Cell Cycle. 2011 Jul 15;10 (14 ):2323-30 - PubMed
  97. N Engl J Med. 2012 Jan 12;366(2):109-19 - PubMed
  98. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17 - PubMed
  99. Oncoimmunology. 2013 Jun 1;2(6):e24677 - PubMed
  100. J Clin Oncol. 2000 Dec 15;18(24):4077-85 - PubMed
  101. Am J Surg Pathol. 2010 Feb;34(2):178-89 - PubMed
  102. Blood. 2014 Dec 11;124(25):3738-47 - PubMed
  103. N Engl J Med. 2014 Mar 20;370(12):1101-10 - PubMed
  104. Nat Rev Clin Oncol. 2011 Dec 20;9(2):76-8 - PubMed
  105. J Clin Invest. 2014 Jun;124(6):2668-82 - PubMed
  106. Nat Rev Drug Discov. 2010 Sep;9(9):665-7 - PubMed
  107. Cancer Discov. 2014 Sep;4(9):OF7 - PubMed
  108. Lancet Oncol. 2014 Aug;15(9):966-74 - PubMed
  109. Expert Rev Hematol. 2014 Jun;7(3):317-9 - PubMed
  110. Semin Cancer Biol. 2012 Feb;22(1):3-13 - PubMed
  111. Annu Rev Immunol. 2013;31:51-72 - PubMed
  112. Nat Rev Drug Discov. 2004 May;3(5):391-400 - PubMed
  113. Cancer Res. 2008 Jul 1;68(13):5301-8 - PubMed
  114. Nat Rev Cancer. 2012 Mar 22;12(4):278-87 - PubMed
  115. Curr Opin Investig Drugs. 2009 Jun;10(6):597-605 - PubMed
  116. Mol Cancer Ther. 2009 May;8(5):1095-105 - PubMed
  117. J Clin Oncol. 2009 Feb 10;27(5):672-80 - PubMed
  118. Nat Biotechnol. 2012 Jul 10;30(7):631-7 - PubMed
  119. J Clin Oncol. 2001 Jul 1;19(13):3244-54 - PubMed
  120. Clin Cancer Res. 2013 Jul 1;19(13):3659-70 - PubMed
  121. Nat Rev Drug Discov. 2012 Jan 03;11(1):19-20 - PubMed
  122. Oncoimmunology. 2013 Apr 1;2(4):e23639 - PubMed
  123. J Clin Invest. 2014 Feb;124(2):812-23 - PubMed
  124. Expert Opin Biol Ther. 2012 Mar;12(3):343-51 - PubMed
  125. Cancer Cell. 2014 Aug 11;26(2):177-89 - PubMed
  126. Lancet. 2014 Jan 4;383(9911):31-9 - PubMed
  127. Oncoimmunology. 2013 Nov 1;2(11):e26494 - PubMed
  128. Lancet Oncol. 2013 Aug;14(9):901-8 - PubMed
  129. Nat Rev Immunol. 2010 May;10(5):317-27 - PubMed
  130. Blood. 2012 Dec 20;120(26):5185-7 - PubMed
  131. Cancer Res. 2013 Nov 1;73(21):6471-83 - PubMed
  132. Clin Cancer Res. 2014 Dec 1;20(23):6059-70 - PubMed
  133. Oncoimmunology. 2013 May 1;2(5):e24436 - PubMed
  134. Oncoimmunology. 2014 Jun 03;3:e29030 - PubMed
  135. Leukemia. 2014 Jan;28(1):230-3 - PubMed
  136. Oncoimmunology. 2012 Jan 1;1(1):28-37 - PubMed
  137. Oncoimmunology. 2013 Oct 1;2(10):e26091 - PubMed
  138. Int J Cancer. 2007 Feb 15;120(4):781-7 - PubMed
  139. Nat Rev Clin Oncol. 2014 Jan;11(1):10-1 - PubMed
  140. Nat Rev Drug Discov. 2010 Apr;9(4):325-38 - PubMed
  141. Maturitas. 1996 Aug;25(1):69-75 - PubMed
  142. Oncoimmunology. 2013 Feb 1;2(2):e23082 - PubMed
  143. Cell Rep. 2012 Aug 30;2(2):257-69 - PubMed
  144. Pharm Res. 2007 Oct;24(10):1910-8 - PubMed
  145. Oncoimmunology. 2013 May 1;2(5):e24238 - PubMed
  146. Cancer Chemother Pharmacol. 2011 Apr;67(4):837-45 - PubMed
  147. N Engl J Med. 2010 Sep 30;363(14):1324-34 - PubMed
  148. Oncoimmunology. 2014 Jun 25;3:e29244 - PubMed
  149. Nat Rev Drug Discov. 2010 Feb;9(2):101-2 - PubMed
  150. Cell Cycle. 2012 Nov 1;11(21):4079-92 - PubMed
  151. Oncoimmunology. 2013 Dec 1;2(12):e26621 - PubMed
  152. Lancet Oncol. 2012 May;13(5):539-48 - PubMed
  153. N Engl J Med. 2014 Jul 17;371(3):213-23 - PubMed
  154. Cancer Res. 2014 Jan 1;74(1):93-103 - PubMed
  155. Cancer Res. 2014 Oct 1;74(19):5561-71 - PubMed
  156. Sci Transl Med. 2013 Oct 16;5(207):207ra144 - PubMed
  157. Cancer Res. 2013 Oct 1;73(19):6024-35 - PubMed
  158. J Immunol. 2011 Mar 15;186(6):3762-9 - PubMed
  159. BMC Cancer. 2011 Jan 18;11:21 - PubMed
  160. Blood. 2014 Jan 30;123(5):678-86 - PubMed
  161. Immunity. 2006 Jan;24(1):19-28 - PubMed
  162. J Clin Oncol. 2012 Jun 20;30(18):2190-6 - PubMed
  163. Ann N Y Acad Sci. 2014 Aug;1321:41-54 - PubMed
  164. Nat Rev Clin Oncol. 2013 Nov;10(11):607 - PubMed
  165. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96 - PubMed
  166. Oncoimmunology. 2012 Jul 1;1(4):477-486 - PubMed
  167. Oncoimmunology. 2013 Apr 1;2(4):e23803 - PubMed
  168. Bioconjug Chem. 2013 Jul 17;24(7):1256-63 - PubMed
  169. Oncoimmunology. 2013 May 1;2(5):e24052 - PubMed
  170. Ann Hematol. 2002 Jan;81(1):26-32 - PubMed
  171. Oncoimmunology. 2013 Dec 1;2(12):e26757 - PubMed
  172. Invest New Drugs. 2014 Oct;32(5):825-37 - PubMed
  173. Clin Cancer Res. 2014 Aug 1;20(15):3902-7 - PubMed
  174. Oncoimmunology. 2013 Jan 1;2(1):e22409 - PubMed
  175. Exp Cell Res. 2011 May 15;317(9):1255-60 - PubMed
  176. Cancer Chemother Pharmacol. 2010 Aug;66(3):413-23 - PubMed
  177. Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):E933-42 - PubMed
  178. Br J Cancer. 2008 Feb 26;98(4):749-55 - PubMed
  179. Oncoimmunology. 2014 Dec 21;3(11):e967147 - PubMed
  180. N Engl J Med. 2006 Dec 14;355(24):2542-50 - PubMed
  181. N Engl J Med. 2014 Jul 17;371(3):273-4 - PubMed
  182. Nat Rev Immunol. 2004 Feb;4(2):153-6 - PubMed
  183. Oncologist. 2011;16(4):497-511 - PubMed
  184. Oncoimmunology. 2012 Jan 1;1(1):103-105 - PubMed
  185. Clin Lymphoma. 2002 Jun;3(1):26-35 - PubMed
  186. J Clin Oncol. 2010 Aug 10;28(23):3701-8 - PubMed

Publication Types